Results 21 to 30 of about 22,889 (244)

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

Gynecologic Oncology, 2023
Objective. To determine whether a non-platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. Methods.
K. Tewari, M. Sill, M. Birrer, R. Penson, Helen Q. Huang, D. Moore, L. Ramondetta, L. Landrum, A. Oaknin, T. Reid, M. Leitao, Helen E. Michael, B. Monk   +12 more
semanticscholar   +1 more source

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-center, phase 1b trial

The Lancet Oncology, 2022
SUMMARY Background: Topotecan is cytotoxic to glioma cells but clinically ineffective due to drug delivery limitations. Systemic delivery is limited by toxicity and insufficient brain penetrance while convection-enhanced delivery has been restricted to a
E. Spinazzi, M. Argenziano, P. Upadhyayula, M. Banu, J. Neira, Dominique M. O. Higgins, Peter B. Wu, B. Pereira, A. Mahajan, N. Humala, O. Al-Dalahmah, Wenting Zhao, A. Save, B. J. Gill, D. Boyett, T. Marie, J. Furnari, T. Sudhakar, S. Stopka, M. Regan, V. Catania, Laura Good, S. Zacharoulis, M. Behl, P.D. Petridis, S. Jambawalikar, A. Mintz, A. Lignelli, N. Agar, P. Sims, M. Welch, A. Lassman, F. Iwamoto, R. D’Amico, J. Grinband, P. Canoll, J. Bruce   +36 more
semanticscholar   +1 more source

Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment

Experimental Eye Research, 2022
Although many more eyes of children with retinoblastoma are salvaged now compared to just 10 years ago, the control of vitreous seeding remains a challenge.
M. D. Del Sole, M. Clausse, P. Nejamkin, Brais Cancela, M. D. Del Rio, G. Lamas, F. Lubieniecki, J. Francis, D. Abramson, G. Chantada, P. Schaiquevich   +10 more
semanticscholar   +1 more source

A phase I and pharmacokinetic study of intraperitoneal topotecan [PDF]

, 2001
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5-30 mg/m(2)) for ...
van der Zee, AGJ, Beijnen, JH, A M E Bos, N H Mulder, L S Hofstra, P H B Willemse, Rosing, H, A G J van der Zee, de Vries, EGE; id_orcid, Hofstra, LS, Willemse, PHB, de Vries, EGE, J H Beijnen, J G Aalders, Mulder, NH, Aalders, JG, E G E de Vries, H Rosing   +17 more
core   +4 more sources

Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study

British Journal of Ophthalmology, 2021
Background Current melphalan-based intravitreal regimens for retinoblastoma (RB) vitreous seeds cause retinal toxicity. We assessed the efficacy and toxicity of topotecan monotherapy compared with melphalan in our rabbit model and patient cohort. Methods
Carley M. Bogan, Jessica V. Kaczmarek, J. Pierce, Sheau-Chiann Chen, K. Boyd, M. Calcutt, T. Bridges, C. Lindsley, Jennifer B Nadelmann, Albert Liao, Terry Hsieh, D. Abramson, J. Francis, D. Friedman, A. Richmond, Anthony B. Daniels   +15 more
semanticscholar   +1 more source

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

The Lancet Oncology, 2020
BACKGROUND Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line ...
N. Baize, I. Monnet, L. Greillier, M. Geier, H. Léna, H. Janicot, A. Vergnenègre, J. Crequit, R. Lamy, J. Auliac, J. Letreut, H. Le Caer, R. Gervais, É. Dansin, A. Madroszyk, P. Renault, G. Le Garff, L. Falchero, H. Bérard, R. Schott, P. Saulnier, C. Chouaid   +21 more
semanticscholar   +1 more source

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in Therapy, 2020
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications.
L. Hart, R. Ferrarotto, Z. Andrić, D. Radosavljević, B. Zarić, W. Hanna, T. Owonikoko, D. Verhoeven, Jie Xiao, S. Morris, J. Antal, M. Hussein   +11 more
semanticscholar   +1 more source

A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan [PDF]

, 2008
A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent topotecan (TPT) is presented. The model includes a novel coupling of both the kinetics of TPT and cell cycle responses to the agent ...
Ali, Reza, Khan, Imtiaz Ali, Godfrey, Keith, Evans, Neil D., Khan, I. A., Errington, Rachel J., Campbell, L., Smith, Paul J., Smith, Paul James, Ali, R., Chappell, M. J. (Michael J.), Chappell, Michael J., Godfrey, K. R., Campbell, Lee, Errington, Rachel Jane, Evans, N. D.   +15 more
core   +1 more source

Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling [PDF]

, 2008
A mathematical multi-cell model for the in vitro kinetics of the anti-cancer agent topotecan (TPT) following administration into a culture medium containing a population of human breast cancer cells (MCF-7 cell line) is described.
Chappell, M. J. (Michael J.), Godfrey, Keith, Godfrey, K. R., Evans, Neil D., Cheung, S. Y. Amy, Errington, Rachel J., Cheung, S. Y. A., Errington, Rachel Jane, Smith, Paul J., Evans, N. D., Smith, Paul James, Chappell, M. J.   +11 more
core   +1 more source

Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport [PDF]

, 2011
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the ...
N.D. Evans, Evans, Neil D., M.J. Chappell, Errington, Rachel J., R.J. Errington, Smith, Paul J., Smith, Paul James, Atari, M. I., Chappell, M. J., P.J. Smith, Chappell, M. J. (Michael J.), M.I. Atari, Errington, Rachel Jane, Evans, N. D.   +13 more
core   +1 more source